# Axitinib (Inlyta)

Source: https://ourhealthnetwork.com/drugs/axitinib
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Axitinib?

Axitinib (brand name: Inlyta) is a kinase inhibitor. It is prescribed to treat carcinoma, renal cell. Across the United States, 762 doctors prescribe Axitinib to approximately 112 Medicare patients.

## Brand names

Inlyta

## Indications

Axitinib is prescribed for the treatment of carcinoma and renal cell.

## Conditions treated

- [Carcinoma](https://ourhealthnetwork.com/conditions/carcinoma)
- [Renal Cell](https://ourhealthnetwork.com/conditions/renal-cell)

## Mechanism of action

Axitinib has been shown to inhibit receptor tyrosine kinases including vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, and VEGFR-3 at therapeutic plasma concentrations. These receptors are implicated in pathologic angiogenesis, tumor growth, and cancer progression.

## Drug classification

- Established Pharmacologic Class: Kinase Inhibitor [EPC]
- Mechanism of Action class: Receptor Tyrosine Kinase Inhibitors [MoA]
- Route of administration: ORAL

## Common side effects

decreased appetite, dysphonia, fatigue, hypertension, hypothyroidism, inlyta in combination with avelumab: diarrhea, mucositis, musculoskeletal pain

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)